Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Income towards Parent Company: 2012-2024

Historic Income towards Parent Company for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $148.4 million.

  • Amphastar Pharmaceuticals' Income towards Parent Company fell 57.09% to $17.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.9 million, marking a year-over-year decrease of 35.76%. This contributed to the annual value of $148.4 million for FY2024, which is 8.91% up from last year.
  • As of FY2024, Amphastar Pharmaceuticals' Income towards Parent Company stood at $148.4 million, which was up 8.91% from $136.2 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Income towards Parent Company registered a high of $148.4 million during FY2024, and its lowest value of $1.1 million during FY2020.
  • For the 3-year period, Amphastar Pharmaceuticals' Income towards Parent Company averaged around $124.1 million, with its median value being $136.2 million (2023).
  • Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 98.27% in 2020, then spiked by 5,689.33% in 2021.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' Income towards Parent Company stood at $1.1 million in 2020, then spiked by 5,689.33% to $63.5 million in 2021, then soared by 38.32% to $87.8 million in 2022, then surged by 55.08% to $136.2 million in 2023, then rose by 8.91% to $148.4 million in 2024.